

**Supplementary Table 23.** Oncogenic / likely oncogenic *MET* TKD mutations in RCC compared to those detected in NSCLC in cohort #2.

| <b>MET residue</b> | <b>MET TKD mutations in RCC<br/>(N=57)</b> | <b>MET TKD mutations in NSCLC<br/>(N=129)</b> | <b>P</b>     |
|--------------------|--|---|--------------|
| H1094X             | 19 (33%)                                   | 46 (35.7%)                                    | 0.86         |
| Y1230X             | 10 (18%)                                   | 12 (9.3%)                                     | 0.13         |
| V1092X             | 9 (16%)                                    | 4 (3.1%)                                      | <b>0.003</b> |
| M1250X             | 5 (8.8%)                                   | 6 (4.7%)                                      | 0.31         |
| D1228X             | 2 (3.5%)                                   | 19 (14.7%)                                    | <b>0.02</b>  |
| L1195X             | 2 (3.5%)                                   | 25 (19.4%)                                    | <b>0.003</b> |
| H1106X             | 2 (3.5%)                                   | 7 (5.4%)                                      | 0.72         |
| F1200X             | 4 (7.0%)                                   | 2 (1.6%)                                      | -            |
| V1220X             | 3 (5.3%)                                   | 3 (2.3%)                                      | -            |
| V1188X             | 1 (1.8%)                                   | 0   | -            |
| F1080X             | 0  | 3 (2.3%)                                      | -            |
| N1100X             | 0  | 1 (0.8%)                                      | -            |
| H1235X             | 0  | 1 (0.8%)                                      | -            |

Abbreviations: NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.

Fisher test was performed only when were present at least 5 cases harboring the specific *MET* TKD mutation in at least one of the tumor type (NSCLC or RCC) compared.